EBS earnings date and last-quarter result: last quarter beat, P/E -44.59. Updated 2026-07-23.
Emergent BioSolutions (EBS) Research Hub
Emergent BioSolutions (EBS) trades on NYSE, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 6.34 USD (+1.77%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -44.59, market cap 0.39B. This hub links to the full technical, earnings and options research available for EBS.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NYSE, US |
| Last close | 6.34 USD (+1.77%) |
| 52-week range | 4.37 USD – 8.54 USD |
| Trend regime | Range |
| 14-day RSI | 35.9 (Bearish) |
| Trailing P/E | -44.59 |
| Market cap | 0.39B |
| Dividend yield | 0.00% |
Available research for EBS
Covered Call on EBS: how it works, illustrative setup around the real 6.34 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on EBS: how it works, illustrative setup around the real 6.34 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on EBS: how it works, illustrative setup around the real 6.34 USD price, max profit/loss, breakeven and when to use it. Educational.
EBS technical analysis: range, last 6.34 USD, RSI 35.9, 52w range 4.37 USD–8.54 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is EBS in?
Emergent BioSolutions (EBS) is classified under Healthcare (Biotechnology), listed on NYSE, US.
Is EBS in an uptrend or downtrend?
As of 2026-10-26, EBS is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is EBS's trailing P/E ratio?
EBS's trailing P/E is -44.59, with a market cap of 0.39B. See the earnings research page for full valuation detail.